SLC2A9 and glioblastoma: In the case of glioblastoma, SWEETs expressed with significant differences were combined with c2.cp.kegg.v7.2.entrez.gmt and c5.go.v7.entrez.gmt, and found that the significantly highly expression of SWEETs (SLC2A10/SLC2A5/SLC2A9) in the WikiPathway database is significantly concentrated in the NRF2 signalling pathway.